Cross-regulation between oncogenic BRAFV600E kinase and the MST1 pathway in papillary thyroid carcinoma

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Lee, Seong Jin ^a,b   Lee, Min Hee ^a   Kim, Dong Wook ^a   Lee, Seongeun ^a   Huang, Songmei ^a   Ryu, Min Jeong ^a   Kim, Yong Kyung ^a   Kim, Sung Jin ^a   Kim, Soung Jung ^a   Hwang, Jung Hwan ^a,c   Oh, Sangphil ^d   Cho, Heeyeong ^b   Kim, Jin Man ^a   Lim, Dae Sik ^d   Jo, Young Suk ^e   Shong, Minho ^a  

^a Chungnam National University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e Chungnam National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MST1 PROTEIN; PROTEIN P21; PROTEIN P27; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR FKHRL1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; CELL CYCLE PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RASSF1 PROTEIN, HUMAN; STK4 PROTEIN, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; ANIMAL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY; PHYSIOLOGY; THYROID TUMOR;

MUS;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MUTATION, MISSENSE; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR CROSS-TALK; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 79251587189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016180     Document Type: Article

References (51)

1. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, et al. (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627.
2. Jo YS, Li S, Song JH, Kwon KH, Lee JC, et al. (2006) Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J ClinEndocrinolMetab 91: 3667-3670.
3. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457.
4. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238-4245.
5. Mitsutake N, Knauf JA, Mitsutake S, Mesa C, Jr., Zhang L, et al. (2005) Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65: 2465-2473.
6. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63: 4561-4567.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
8. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202.
9. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, et al. (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66: 999-1006.
10. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, et al. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759.
11. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, et al. (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412-2421.
12. Packer LM, East P, Reis-Filho JS, Marais R (2009) Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res 22: 785-798.
13. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, et al. (2009) (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. ProcNatlAcadSci U S A 106: 4519-4524.
14. Uribe P, Andrade L, Gonzalez S (2006) Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 126: 161-166.
15. Zou H, Harrington JJ, Shire AM, Rego RL, Wang L, et al. (2007) Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev 16: 2686-2696.
16. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221.
17. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, et al. (2002) Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62: 3698-3701.
18. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, et al. (2004) Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 64: 1664-1668.
19. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, et al. (2006) A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 125: 987-1001.
20. Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, et al. (2006) Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 66: 2562-2569.
21. Vichalkovski A, Gresko E, Cornils H, Hergovich A, Schmitz D, et al. (2008) NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis. CurrBiol 18: 1889-1895.
22. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, et al. (2005) RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest 85: 1065-1075.
23. Jung HS, Kim DW, Jo YS, Chung HK, Song JH, et al. (2005) Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/ PTC kinases. MolEndocrinol 19: 2748-2759.
24. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, et al. (2009) Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15: 7538-7546.
25. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, et al. (2008) ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10: 138-148.
26. Guo S, Rena G, Cichy S, He X, Cohen P, et al. (1999) Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J BiolChem 274: 17184-17192.
27. Lee KK, Ohyama T, Yajima N, Tsubuki S, Yonehara S (2001) MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J BiolChem 276: 19276-19285.
28. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, et al. (2004) The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6: 129-137.
29. Tang ED, Nunez G, Barr FG, Guan KL (1999) Negative regulation of the forkhead transcription factor FKHR by Akt. J BiolChem 274: 16741-16746.
30. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, et al. (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J ClinEndocrinolMetab 88: 4393-4397.
31. Oh S, Lee D, Kim T, Kim TS, Oh HJ, et al. (2009) Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse. Mol Cell Biol 29: 6309-6320.
32. Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, et al. (2005)Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J ClinEndocrinolMetab 90: 4011-4018.
33. Obsil T, Obsilova V (2008) Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene 27: 2263-2275.
34. van der Heide LP, Smidt MP (2005) Regulation of FoxO activity by CBP/p300- mediated acetylation. Trends BiochemSci 30: 81-86.
35. van der Horst A, Burgering BM (2007) Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 8: 440-450.
36. Nemoto S, Finkel T (2002) Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295: 2450-2452.
37. O'Neill E, Kolch W (2005) Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle 4: 365-367.
38. O'Neill E, Rushworth L, Baccarini M, Kolch W (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306: 2267-2270.
39. Kyriakis JM (2007) The integration of signaling by multiprotein complexes containing Raf kinases. BiochimBiophysActa 1773: 1238-1247.
40. Harvey KF, Pfleger CM, Hariharan IK (2003) The Drosophila Mstortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 114: 457-467.
41. Pantalacci S, Tapon N, Leopold P (2003) The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 5: 921-927.
42. Wu S, Huang J, Dong J, Pan D (2003) Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114: 445-456.
43. Medema RH, Kops GJ, Bos JL, Burgering BM (2000) AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787.
44. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Jr., et al. (2006) BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RASBRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147: 1014-1019.
45. Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885.
46. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, et al. (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61: 8659-8663.
47. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, et al. (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8: 514-519.
48. Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28: 742-762.
49. Cinar B, Fang PK, Lutchman M, Di Vizio D, Adam RM, et al. (2007) The proapoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. Embo J 26: 4523-4534.
50. Jang SW, Yang SJ, Srinivasan S, Ye K (2007) Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J BiolChem 282: 30836-30844.
51. Hwang E, Ryu KS, Paakkonen K, Guntert P, Cheong HK, et al. (2007) Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway. ProcNatlAcadSci U S A 104: 9236-9241.